Powerup Acquisition CORP 8-K filings

PowerUp Acquisition Corp. has entered into a loan agreement with Blackstone Capital Advisors, Inc. for up to $500,000, with an initial draw of $184,543.80, to support its merger with Aspire Biopharma.

PowerUp Acquisition Corp. and Aspire Biopharma have agreed to extend the deadline for delivering disclosure schedules related to their merger agreement to October 11, 2024.

PowerUp Acquisition Corp. will pay its sponsor a $1 million fee upon the successful closing of a business combination with Aspire Biopharma, after a previous deal with Visiox Pharmaceuticals was terminated.

PowerUp Acquisition Corp. and Aspire Biopharma have amended their merger agreement, adjusting the merger consideration, equity incentive plan size, and extending the due diligence period.

PowerUp Acquisition Corp. will merge with Aspire Biopharma, valuing Aspire at approximately $316 million pre-money, to form a Nasdaq-listed biopharmaceutical company.

PowerUp Acquisition Corp. has entered into a definitive agreement to merge with Aspire Biopharma, Inc., creating a combined entity focused on novel drug delivery mechanisms.

PowerUp Acquisition Corp. has terminated its merger agreement with Visiox Pharmaceuticals due to unmet closing conditions.

PowerUp Acquisition Corp. and Visiox Pharmaceuticals have amended their merger agreement, extending the closing date to June 30, 2024, and modifying several financial and operational conditions.

PowerUp Acquisition Corp. has successfully extended its deadline to complete a business combination to February 17, 2025, and removed a restriction on minimum net tangible assets.

PowerUp Acquisition Corp. has entered into a non-redemption agreement with a third-party shareholder to maintain funds in its trust account, offering shares in exchange for not redeeming their holdings.

PowerUp Acquisition Corp. has further postponed its shareholder meeting to May 22, 2024, while entering into non-redemption agreements to secure funds in its trust account.

PowerUp Acquisition Corp. has postponed its extraordinary general meeting of shareholders to May 21, 2024, to vote on extending the deadline for completing a business combination.